“The UK is the best place in the world to run trials, with consequent ‘wealth and health’ benefits,” so says Philip Johnson, Director of the Cancer Research UK Clinical Trails Unit
as well as Professor of Oncology and Translational Research at the University of Birmingham. In The New Optimists he argues why clinical trials are so important, and the kind of impact they have on treatments and patient care across the world.
Professor Johnson developed his interest in clinical trials and hepatobiliary cancer whilst at the Institute of Liver Studies, Kings College Hospital, London where he subsequently became Assistant Director. In 1992, he was appointed to the Chair of Clinical Oncology at the Chinese University of Hong Kong where he also became Director of the Cancer Centre and developed the Comprehensive Clinical Trials Unit whilst furthering his research interests into molecular biomarkers of cancer and new approaches to the treatment of live cancer.